Sanofi and Lonza partner on a €270M biologics plant that will employ 200

Work on the initial phase of a new biologics plant will begin this year at Lonza's site in Visp, Switzerland.

Sanofi and Swiss contractor Lonza will share the cost of building a €270 million ($286.3 million) plant as Sanofi again turns to a partner to help carry the financial burden of expanding capacity for new biologic meds.

The plant, which is expected to employ 200, will be built at Lonza's site in Visp, Switzerland. Work on the initial phase will start this year and is slated to be complete at the end of 2019 and operational in 2020.

Philippe Luscan, Sanofi’s executive VP of Global Industrial Affairs, said Sanofi needs the extra capacity because 60% of the French drugmaker’s pipeline is made of biologics, including monoclonal antibodies.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“In addition to the investments we are making in building our own internal production capabilities, the joint venture between Sanofi and Lonza emphasizes our commitment to provide access for patients to high quality therapeutic monoclonal antibodies,” Luscan said in a statement.

Under the deal, Lonza will build the new facility at its Visp site, where it currently employs 2,700,  and the two will jointly operate it. Lonza has previously built three other biologics plants, including in the U.S. and one in Singapore. Lonza will be able to use its half of the capacity for products for other companies, if it is not needed to do work for Sanofi. Also, if any of Sanofi’s capacity is not being utilized at some point, Lonza will be allowed to use it for its own work.

Sanofi has turned to a partner before for help in the production of monoclonal antibodies, known as mAbs. Two years ago it transferred production of mAbs it was working on with its sometimes-partner Regeneron to a Boehringer Ingelheim plant in Germany. At that time, Sanofi said that 72% of its current R&D projects involved biologics, with nearly half of those being mAbs.

Sanofi’s own production work with mAbs has not always been stellar. In October, the drugmaker received a complete response letter tied to problems at a fill/finish plant in France, delaying approval of sarilumab, an expected blockbuster that it is developing with Regeneron. Sanofi CEO Olivier Brandicourt has said a couple of times recently that the company has gotten indications from the FDA that its responses to the issues are on point and that it expects a reinspection soon. 

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.